BioNTech (BNTX)
(Delayed Data from NSDQ)
$96.31 USD
-1.84 (-1.87%)
Updated Sep 18, 2025 04:00 PM ET
After-Market: $96.55 +0.24 (0.25%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTX 96.31 -1.84(-1.87%)
Will BNTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for BNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BNTX
MRNA Stock Rises as Updated COVID-19 Jab Shows Strong Immune Response
COVID-19 Vaccine Stocks Fall on Reports Linking Shots to Child Deaths
BNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains?
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold?
SMMT Stock Plummets 25% on Regional Data Differences in NSCLC Study
Other News for BNTX
CDC vaccines panel head Kulldorff challenges former directors to debate
New York issues its own COVID-19 vaccine guidance
Is BNTX coiling for a breakout? Calm After Storm shows up after sliding 1.12%
U.S. health insurers pledge continuing coverage of COVID shots ahead of ACIP meeting
Former CDC Director Monarez says RFK Jr. fired her for not following two directives